JP2001523088A - 毒性ショック症候群の兆候を減じるのに有用なペプチド類 - Google Patents
毒性ショック症候群の兆候を減じるのに有用なペプチド類Info
- Publication number
- JP2001523088A JP2001523088A JP54294198A JP54294198A JP2001523088A JP 2001523088 A JP2001523088 A JP 2001523088A JP 54294198 A JP54294198 A JP 54294198A JP 54294198 A JP54294198 A JP 54294198A JP 2001523088 A JP2001523088 A JP 2001523088A
- Authority
- JP
- Japan
- Prior art keywords
- twenty
- group
- peptide
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 140
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 63
- 231100000650 Toxic shock syndrome Toxicity 0.000 title abstract description 23
- 206010040070 Septic Shock Diseases 0.000 title abstract description 21
- 206010044248 Toxic shock syndrome Diseases 0.000 title abstract description 21
- 231100000765 toxin Toxicity 0.000 claims abstract description 79
- 239000003053 toxin Substances 0.000 claims abstract description 78
- 108700012359 toxins Proteins 0.000 claims abstract description 77
- 241000191940 Staphylococcus Species 0.000 claims abstract description 44
- 241000194017 Streptococcus Species 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 41
- 210000002966 serum Anatomy 0.000 claims abstract description 33
- 241000124008 Mammalia Species 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 231100000331 toxic Toxicity 0.000 claims abstract description 10
- 230000002588 toxic effect Effects 0.000 claims abstract description 10
- 150000001413 amino acids Chemical group 0.000 claims description 59
- 230000001698 pyrogenic effect Effects 0.000 claims description 56
- 231100000776 exotoxin Toxicity 0.000 claims description 51
- 239000002095 exotoxin Substances 0.000 claims description 51
- 235000001014 amino acid Nutrition 0.000 claims description 48
- 229940024606 amino acid Drugs 0.000 claims description 48
- 229910052740 iodine Inorganic materials 0.000 claims description 32
- 229910052720 vanadium Inorganic materials 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 21
- 229910052700 potassium Inorganic materials 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 231100000655 enterotoxin Toxicity 0.000 claims description 18
- 241001415395 Spea Species 0.000 claims description 15
- 108091035707 Consensus sequence Proteins 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 230000013020 embryo development Effects 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 241000295644 Staphylococcaceae Species 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 108700037929 Streptococcus pyogenes SpeA Proteins 0.000 claims 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 1
- 229910052793 cadmium Inorganic materials 0.000 claims 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 1
- 150000002605 large molecules Chemical class 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 17
- 229920000642 polymer Polymers 0.000 abstract description 13
- 230000004044 response Effects 0.000 abstract description 6
- 208000035143 Bacterial infection Diseases 0.000 abstract description 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
- 230000028993 immune response Effects 0.000 abstract description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 28
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 19
- 230000002788 anti-peptide Effects 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000147 enterotoxin Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- -1 Amino acids Chemical class 0.000 description 4
- 231100000699 Bacterial toxin Toxicity 0.000 description 4
- 101710146739 Enterotoxin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000000688 bacterial toxin Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 108010022946 erythrogenic toxin Proteins 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 102220201851 rs143406017 Human genes 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 101001023095 Anemonia sulcata Delta-actitoxin-Avd1a Proteins 0.000 description 1
- 101000641989 Araneus ventricosus Kunitz-type U1-aranetoxin-Av1a Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101001028691 Carybdea rastonii Toxin CrTX-A Proteins 0.000 description 1
- 101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 description 1
- 101000685085 Centruroides noxius Toxin Cn1 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101001028688 Chironex fleckeri Toxin CfTX-1 Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 101000644407 Cyriopagopus schmidti U6-theraphotoxin-Hs1a Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 101000679608 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) Cysteine rich necrotrophic effector Tox1 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229910000498 pewter Inorganic materials 0.000 description 1
- 239000010957 pewter Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アミノ酸配列:X25X26YGGX1TX2X3X4X5N(配列番号28)およびアミノ酸配 列:KX6X7X8X9X10X11X12X13DX14X15X16RX17X18X27X19X20X21X22X23X24Y(配列番 号29)(式中、X1,X8,X13およびX24はL,IおよびVからなる群から別個に選 択され;X2,X4,X3,X6,X7,X9,X10,X11,X12,X14,X15,X16,X17,X18, X19,X20,X21,X22,およびX23は任意のアミノ酸からなる群から別個に選択さ れ;そしてX3,X25およびX26は任意のアミノ酸および非アミノ酸からなる群から 別個に選択され;そして、X27はLおよびYからなる群から選択される) からなる群から選択されるコンセンサス配列を有するペプチド。 2.X2がL,E,K,P,およびNからなる群から選択され; X3がHおよびAまたは非アミノ酸からなる群から選択され; X4がD,N,E,Q,およびHからなる群から選択され; X5がN,G,S,およびRからなる群から選択され; X6がKおよびDからなる群から選択され; X7がN,K,S,E,M,I,およびQからなる群から選択され; X9がTおよびAからなる群から選択され; X10がV,A,L,F,およびIからなる群から選択され; X11がQおよびSからなる群から選択され; X12がEおよびTからなる群から選択され; X14がL,Y,I,A,F,およびCからなる群から選択され; X15がQ,L,K,およびEからなる群から選択され; X16がA,T,I,およびVからなる群から選択され; X17がR,H,N,およびKからなる群から選択され; X18がY,F,I,L,およびQからなる群から選択され; X19がQ,V,I,H,S,T,およびMからなる群から選択され; X20がE,K,N,G,D,S,およびQからなる群から選択され; X21がK,N,D,R,およびIからなる群から選択され; X22がY,K,L,F,およびHからなる群から選択され; X23がN,K,G,およびQからなる群から選択され; X25がM,T,L,Iおよび非アミノ酸からなる群から選択され;そして X26がM,T,L,Iおよび非アミノ酸からなる群から選択される、 請求項1記載のペプチド。 3.X1=バリン;X2=ロイシン;X3=ヒスチジン;X4=グルタミン酸;X5=グ リシン;X6=リジン;X7=アスパラギン;X8=バリン;X9=スレオニン;X10= バリン;X11=グルタミン;X12=グルタミン酸;X13=ロイシン;X14=ロイシン 、チロシン、イソロイシンまたはフェニルアラニン;X15=リジン;X16=アラニ ン;X17=リジン;X18=チロシン;X19=グルタミン、バリンまたはスレオニン ;X20=アスパラギン酸;X21=リジン;X22=リジン;X23=リジン;X24=ロイ シン;X25=システイン;X26=メチオニン;そしてX27=ロイシンである、請求 項1記載のペプチド。 4.CMYGGVTEHEGN(配列番号3)、CMYGGVTEHEGNGC(配列番号5)、KKNVTVQELDYK IRKYLVDNKKLY(配列番号4)、CGKKNVTVQELDYKIRKYLVDNKKLYGC(配列番号6)、CMYG GVTEHEGNKKNVTVQELDYKIRKYLVDNKKLY(配列番号7)、およびCMYGGVTEHEGNKKNVTVQE LDYKIRKYLVDNKKLYGC(配列番号8)からなる群から選択される少なくとも一つの アミノ酸配列を含むペプチド。 5.アミノ酸配列:CMYGGVTEHEGNKKNVTVQELDYKIRKYLVDNKKLYGC(配列番号8) を含む、請求項4記載のペプチド。 6.アミノ酸配列が少なくとも6,000から8,000ドルトンの大きな分子の成分で ある、請求項4記載のペプチド。 7.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,X2 4 がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10,X1 1 ,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意のアミ ノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸および 非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYからなる 群から別個に選択される) からなる群から選択されるコンセンサスアミノ酸配列を含むペプチドを含む、生 理学上受容可能な担体中の薬学組成物。 8.請求項4のペプチドを生理学上受容可能な担体中に含む、薬学組成物。 9.抗体の生成を引き出すのに十分な量の、X25X26YGGX1TX2X3X4X5N(配列番 号28)およびKX6X7X8X9X10X11X12X13DX14X15X16RX17X18X27X19X20X21X22X23X24Y (配列番号29)(式中、X1,X8,X13,およびX24がL,IおよびVからなる群か ら選択され;X2,X4,X5,X6,X7,X9,X10,X11,X12,X14,X15,X16,X17,X18 ,X19,X20,X21,X22およびX23は任意のアミノ酸からなる群から別個に選択 され;X3,X25およびX26は任意のアミノ酸および非アミノ酸からなる群から別個 に選択され;そして、X27はLおよびYからなる群から別個に選択される)からな る群から選択されるコンセンサスアミノ酸配列を含む、生理学上受容可能な担体 中のペプチドを、哺乳類に投与することからなる、スタフィロコッカス腸毒素ま たはストレプトコッカス発熱性外毒素の少なくとも一つに結合する血清抗体を誘 導する方法。 10.約5マイクログラムから約100マイクログラムの投薬量でペプチドを投与 する、請求項9記載の方法。 11.抗体の生成を引き出すのに十分な量の、生理学上受容可能な担体中の請求 項4記載のペプチドを哺乳類に投与することからなる、スタフィロコッカス腸毒 素またはストレプトコッカス発熱性外毒素の少なくとも一つに結合する血清抗体 を誘導する方法。 12.ペプチドがアミノ酸配列:CMYGGVTEHEGNKKNVTVQELDYKIRKYLVDNKKLYGC(配 列番号8)を含む、請求項11記載の方法。 13.約5マイクログラムから約100マイクログラムの投薬量でペプチドを投与 する、請求項11記載の方法。 14.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,お よびX24がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10 ,X11,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意 のアミノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸 および非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYか らなる群から別個に選択される)からなる群から選択されるコンセンサスアミノ 酸配列を含む、免疫学上十分な量の、生理学上受容可能な担体中のペプチドを、 哺乳類に投与することからなる、毒素SPEA,SEA,SEB,およびSEDを検出する抗 体を誘導する方法。 15.免疫学上十分な量の、生理学上受容可能な担体中の請求項4記載のペプチ ドを、哺乳類に投与することからなる、毒素SPEA,SEA,SEB,およびSEDを検出 する抗体を誘導する方法。 16.ペプチドがアミノ酸配列:CMYGGVTEHEGNKKNVTVQELDYKIRKYLVDNKKLYGC(配 列番号8)を含む、請求項15記載の方法。 17.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,お よびX24がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10 ,X11,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意 のアミノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸 および非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYか らなる群から別個に選択される)からなる群から選択されるコンセンサスアミノ 酸配列を含む、免疫学上十分な量の、生理学上受容可能な担体中のペプチドを、 哺乳類に投与することからなる、毒素SEA,SEB,SEC,SEE,SPEAまたはSPECの何 れか一つの存在下でヒト単核細胞の胚発生を阻害する血清抗体を誘導する方法。 18.免疫学上十分な量の、生理学上受容可能な担体中の請求項4記載のペプチ ドを、哺乳類に投与することからなる、毒素SEA,SEB,SEC,SEE,SPEAまたはSP ECの何れか一つの存在下でヒト単核細胞の胚発生を阻害する血清抗体を誘導する 方法。 19.ペプチドがアミノ酸配列:CMYGGVTEHEGNKKNVTVQELDYKIRKYLVDNKKLYGC(配 列番号8)を含む、請求項18記載の方法。 20.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,お よびX24がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10 ,X11,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意 のアミノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸 および非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYか らなる群から別個に選択される)からなる群から選択されるコンセンサスアミノ 酸配列を含むペプチドで抗体産生細胞を免疫することにより誘導される抗体を含 む組成物を免疫学上十分な量インビボにおいて投与するこ とからなる、スタフィロコッカスおよびストレプトコッカスの毒素の毒性作用に 対して哺乳類を受動免疫する方法。 21.請求項4記載のペプチドで抗体産生細胞を免疫することにより誘導される 抗体を含む組成物を免疫学上十分な量インビボにおいて投与することからなる、 スタフィロコッカスおよびストレプトコッカスの毒素の毒性作用に対して哺乳類 を受動免疫する方法。 22.ペプチドがアミノ酸配列:CMYGGVTEHEGNKKNVTVQELDYKIRKYLVDNKKLYGC(配 列番号8)を含む、請求項21記載の方法。 23.約1mg/kg哺乳類体重から約10mg/kg哺乳類体重の範囲の投薬量で抗体組成 物を投与する、請求項20または21記載の方法。 24.哺乳類がヒトである、請求項9、11、14、15、17、18、20または21記載の 方法。 25.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,お よびX24がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10 ,X11,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意 のアミノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸 および非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYか らなる群から別個に選択される)からなる群から選択されるコンセンサスアミノ 酸配列を含むペプチドをコードする核酸。 26.請求項4記載のアミノ酸配列少なくとも一つをコードする核酸。 27.核酸によりコードされるアミノ酸配列がCMYGGVTEHEGNKKNVTVQELDYKIRKYLV DNKKLYGC(配列番号8)である、請求項26記載の核酸。 28.請求項25記載の核酸を含む宿主細胞。 29.請求項26記載の核酸を含む宿主細胞。 30.コードされたペプチドを免疫学上十分な量生産することにより抗体を引き 出す、生理学上受容可能な担体中の請求項25記載の核酸を哺乳類に投与すること からなる、スタフィロコッカス腸毒素またはストレプトコッカス発熱性外毒素の 少なくとも一つに結合する血清抗体を誘導する方法。 31.コードされたペプチドを免疫学上十分な量生産することにより抗体を引き 出す、生理学上受容可能な担体中の請求項26記載の核酸を哺乳類に投与すること からなる、スタフィロコッカス腸毒素またはストレプトコッカス発熱性外毒素の 少なくとも一つに結合する血清抗体を誘導する方法。 32.請求項9、11、14、15、17、および19の何れかに記載の方法により作成さ れた抗体。 33.請求項32記載の抗体をサンプルと接触させ、そして毒素に結合した抗体を 検出することからなる、サンプル中のスタフィロコッカスまたはストレプトコッ カスの毒素の存在を検出する方法。 34.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,お よびX24がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10 ,X11,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意 のアミノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸 および非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYか らなる群から別個に選択される)からなる群から選択されるコンセンサスアミノ 酸配列を含むペプチドをサンプルと接触させ、そして抗体ヘのペプチドの結合を 検出することからなる、サンプル中のスタフィロコッカスまたはストレプトコッ カスの毒素に対する抗体の存在を検出する方法。 35.請求項4記載のペプチドをサンプルと接触させ、そして抗体へのペプチド の結合を検出することからなる、サンプル中のスタフィロコッカスまたはストレ プトコッカスの毒素に対する抗体の存在を検出する方法。 36.請求項32記載の抗体を含む、サンプル中のスタフィロコッカスまたはスト レプトコッカスの毒素の存在を検出するためのキット。 37.X25X26YGGX1TX2X3X4X5N(配列番号28)およびKX6X7X8X9X10X11X12X13DX14 X15X16RX17X18X27X19X20X21X22X23X24Y(配列番号29)(式中、X1,X8,X13,お よびX24がL,IおよびVからなる群から選択され;X2,X4,X5,X6,X7,X9,X10 ,X11,X12,X14,X15,X16,X17,X18,X19,X20,X21,X22およびX23は任意 のアミノ酸からなる群から別個に選択され;X3,X25およびX26は任意のアミノ酸 および非アミノ酸からなる群から別個に選択され;そして、X27はLおよびYか らなる群から別個に選択される)からなる群から選択されるコンセンサスアミノ 酸配列を含むペプチドを含む、サンプル中のスタフィロコ ッカスまたはストレプトコッカスの毒素に対する抗体の存在を検出するためのキ ット。 38.請求項4記載のペプチドを含む、サンプル中のスタフィロコッカスまたは ストレプトコッカスの毒素に対する抗体の存在を検出するためのキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/838,413 | 1997-04-07 | ||
US08/838,413 US6075119A (en) | 1997-04-07 | 1997-04-07 | Peptides useful for reducing symptoms of toxic shock syndrome |
PCT/US1998/006663 WO1998045325A1 (en) | 1997-04-07 | 1998-04-01 | Peptides useful for reducing symptoms of toxic shock syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001523088A true JP2001523088A (ja) | 2001-11-20 |
Family
ID=25277036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54294198A Ceased JP2001523088A (ja) | 1997-04-07 | 1998-04-01 | 毒性ショック症候群の兆候を減じるのに有用なペプチド類 |
Country Status (6)
Country | Link |
---|---|
US (3) | US6075119A (ja) |
EP (1) | EP0973803A1 (ja) |
JP (1) | JP2001523088A (ja) |
AU (1) | AU744477B2 (ja) |
CA (1) | CA2286346A1 (ja) |
WO (1) | WO1998045325A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007524378A (ja) * | 2003-03-28 | 2007-08-30 | ザ ロックフェラー ユニヴァーシティ | 中毒性ショック症候群及び敗血症性ショック症状を緩和するペプチド及び模倣体 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
NZ502745A (en) * | 1997-07-21 | 2003-02-28 | Pharmacia & Upjohn Ab | Use of superantigen conjugates for the directed cytolysis of target cells |
US6872394B1 (en) * | 1997-12-02 | 2005-03-29 | Idaho Research Foundation, Inc. | Non-toxic immune stimulating enterotoxin compositions |
US6632640B1 (en) * | 1998-07-10 | 2003-10-14 | The United States Of America As Represented By The Secretary Of The Army | Vaccine against Staphylococcus intoxication |
CA2345023A1 (en) * | 1998-10-07 | 2000-04-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
WO2000078790A2 (en) * | 1999-06-18 | 2000-12-28 | The Rockefeller University | Methods for inhibiting hiv replication |
DE10116042A1 (de) * | 2001-03-30 | 2002-10-24 | Fresenius Hemocare Gmbh | Exotoxin-Ligand |
US20040236082A1 (en) * | 2001-04-13 | 2004-11-25 | Marshall Matthew J. | Modified staphylococcal enterotoxins and expression systems therefore |
FI20012082A0 (fi) | 2001-10-26 | 2001-10-26 | Paeivi Liesi | Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi |
AU2003214972A1 (en) * | 2002-02-01 | 2003-09-02 | University Of Maryland | Identification of epitopes on staphylococcal enterotoxins that inhibit transcytosis |
US20070178113A1 (en) * | 2005-11-22 | 2007-08-02 | Backstrom B T | Superantigen conjugate |
MX2020012245A (es) * | 2018-05-16 | 2021-01-29 | Univ Griffith | Sindrome de choque toxico estreptococico. |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728388A (en) * | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
EP0511306B1 (en) * | 1990-01-17 | 2002-07-17 | TERMAN, David S. | Tumor killing effects of enterotoxins and related compounds |
WO1993024136A1 (en) * | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5378607A (en) * | 1991-07-29 | 1995-01-03 | Biomide Investment Limited Partnership | Method for testing for the presence of metastatic tumor cells |
US5529934A (en) * | 1991-07-29 | 1996-06-25 | Biomide Investment Limited Partnership | Method for measuring blood procoagulant activity of human leukocyte antigens |
JPH0549477A (ja) * | 1991-08-05 | 1993-03-02 | Wakunaga Pharmaceut Co Ltd | スタフイロコツカス属細菌類の検出 |
WO1994020124A1 (en) * | 1992-06-01 | 1994-09-15 | Terman David S | Method of cancer treatment |
US5545716A (en) * | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
US5585465A (en) * | 1993-04-05 | 1996-12-17 | National Jewish Center For Immunology And Respiratory Medicine | Isolated toxin associated with Kawasaki syndrome |
US5470716A (en) * | 1993-04-05 | 1995-11-28 | National Jewish Center For Immunology And Respiratory Medicine | Method for diagnosing kawasaki syndrome |
US5476767A (en) * | 1993-04-05 | 1995-12-19 | Regents Of The University Of Minnesota | Isolated nucleic acid molecule coding for toxin associated with Kawasaki Syndrome and uses thereof |
WO1994025483A1 (en) * | 1993-05-03 | 1994-11-10 | The University Of British Columbia | Immunotherapeutic peptides derived from toxic shock syndrome toxin-1, antibodies thereto, their uses in pharmaceutical compositions and diagnosis |
US5519114A (en) * | 1993-10-29 | 1996-05-21 | University Of Florida Research Foundation, Inc. | Retroviral superantigens, superantigen peptides, and methods of use |
US5601830A (en) * | 1995-03-31 | 1997-02-11 | Wisconsin Alumni Research Foundation | Staphylococcus aureus enterotoxin H and methods of use |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
EP1538208A3 (en) * | 1995-06-07 | 2007-05-23 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin A and methods of use |
IL119938A (en) | 1996-12-30 | 2005-08-31 | Yissum Res Dev Co | Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
CA2295440A1 (en) | 1997-06-18 | 1998-12-23 | The Rockefeller University | Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof |
-
1997
- 1997-04-07 US US08/838,413 patent/US6075119A/en not_active Expired - Fee Related
-
1998
- 1998-04-01 AU AU69501/98A patent/AU744477B2/en not_active Ceased
- 1998-04-01 EP EP98915277A patent/EP0973803A1/en not_active Withdrawn
- 1998-04-01 WO PCT/US1998/006663 patent/WO1998045325A1/en not_active Application Discontinuation
- 1998-04-01 JP JP54294198A patent/JP2001523088A/ja not_active Ceased
- 1998-04-01 CA CA002286346A patent/CA2286346A1/en not_active Abandoned
-
1999
- 1999-06-18 US US09/335,581 patent/US7115268B1/en not_active Expired - Fee Related
-
2006
- 2006-10-03 US US11/542,774 patent/US20080305109A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007524378A (ja) * | 2003-03-28 | 2007-08-30 | ザ ロックフェラー ユニヴァーシティ | 中毒性ショック症候群及び敗血症性ショック症状を緩和するペプチド及び模倣体 |
Also Published As
Publication number | Publication date |
---|---|
WO1998045325A1 (en) | 1998-10-15 |
US20080305109A1 (en) | 2008-12-11 |
EP0973803A1 (en) | 2000-01-26 |
US6075119A (en) | 2000-06-13 |
US7115268B1 (en) | 2006-10-03 |
AU744477B2 (en) | 2002-02-28 |
AU6950198A (en) | 1998-10-30 |
CA2286346A1 (en) | 1998-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7795402B2 (en) | Anti-Staphylococcus aureus antibodies | |
EP1412379B1 (en) | Vaccine | |
RU2529946C2 (ru) | Моноклональное антитело человека против альфа-токсина из s. aureus и его применение в лечении или предотвращении образования абсцесса | |
AU2007200937A8 (en) | Antigenic polypeptides | |
AU2001274248A1 (en) | Antigenic polypeptides | |
US20080305109A1 (en) | Method of passive immunization | |
AU2013251165A1 (en) | Cross-reactive Staphylococcus aureus antibody | |
JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
US20160074497A1 (en) | Staphylococcus live cell vaccines | |
US20080299127A1 (en) | Protective staphylococcus aureus vaccine based on cell wall-associated proteins | |
Tsurumi et al. | Production of antibody against a synthetic peptide of Porphyromonas gingivalis 40-kDa outer membrane protein | |
JP2003517445A (ja) | 毒性ショック症候群および敗血症性ショックの兆候を減少させるのに有用なペプチド | |
US11278609B2 (en) | Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies | |
WO2023247747A1 (en) | Protective staphylococcal exotoxin vaccine | |
WO2004087742A2 (en) | Peptides for reducing symptoms of toxic shock syndrome and septic shck |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071023 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071203 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080422 |